World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 30580315

Number of visits today: 7523

Number of downloads: 12955597

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Holmberg H, Elm T, Karpf D, Tranholm M, Bjørn SE, Stennicke H, Ezban M. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa: Letters to the Editor. Journal of Thrombosis and Haemostasis 2011;9:1070-2. [DOI: 10.1111/j.1538-7836.2011.04252.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]

For:

Holmberg H, Elm T, Karpf D, Tranholm M, Bjørn SE, Stennicke H, Ezban M. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa: Letters to the Editor. Journal of Thrombosis and Haemostasis 2011;9:1070-2. [DOI: 10.1111/j.1538-7836.2011.04252.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]

Number	Citing Articles
1	Giorgi ME, Agusti R, de Lederkremer RM. Glycan-targeted PEGylation for selective modification of proteins. Polymer-Protein Conjugates. Elsevier; 2020. pp. 235-50. [DOI: 10.1016/b978-0-444-64081-9.00011-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2	Mannucci PM, Mancuso ME. Investigational drugs for coagulation disorders. Expert Opinion on Investigational Drugs 2013;22:945-53. [DOI: 10.1517/13543784.2013.798302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
3	Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015;113:165-76. [PMID: 25274414 DOI: 10.1160/TH14-04-0332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
4	Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; The Pioneer™1 Investigators. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. J Thromb Haemost 2013;11:1260-8. [DOI: 10.1111/jth.12237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
5	Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014;12:220-8. [PMID: 24641308 DOI: 10.1111/jth.12477] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
6	Agersø H, Stennicke HR, Pelzer H, Olsen EN, Merricks EP, Defriess NA, Nichols TC, Ezban M. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia 2012;18:941-7. [PMID: 22812621 DOI: 10.1111/j.1365-2516.2012.02896.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]